skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Smoothened Antagonist LEQ506 (Code C91089)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Smoothened Antagonist LEQ506

Definition: An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway, thereby inhibiting tumor cell growth. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Dysregulated activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.

Display Name: Smoothened Antagonist LEQ506

Label: Smoothened Antagonist LEQ506

NCI Thesaurus Code: C91089 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL421477  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
LEQ506
Smoothened Antagonist LEQ506

External Source Codes: 
PDQ Closed Trial Search ID 671850
PDQ Open Trial Search ID 671850 (check for NCI PDQ open clinical trial info)
NCI META CUI CL421477

Other Properties:
Name Value (qualifiers indented underneath)
code C91089
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91089

Mainbox Bottom